December 12, 2016
Novocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel may be Safe as First-Line Treatment and may Improve Survival of Patients with Recurrent Ovarian Cancer
Topline results demonstrate strong efficacy signals and support planning of phase 3 pivotal trial of TTFields in recurrent ovarian cancer Topline results demonstrate strong efficacy signals and support planning of phase 3 pivotal trial of TTFields in recurrent ovarian cancer December 12, 2016 04:00 PM Eastern… Read More
learn more
December 12, 2016
Novocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel may be Safe as First-Line Treatment and may Improve Survival of Patients with Recurrent Ovarian Cancer
Topline results demonstrate strong efficacy signals and support planning of phase 3 pivotal trial of TTFields in recurrent ovarian cancer Topline results demonstrate strong efficacy signals and support planning of phase 3 pivotal trial of TTFields in recurrent ovarian cancer December 12, 2016 04:00 PM Eastern… Read More
learn more
December 8, 2016
Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016
Speakers will share new data from Novocure’s phase 2 pilot trials in pancreatic and ovarian cancers Speakers will share new data from Novocure’s phase 2 pilot trials in pancreatic and ovarian cancers December 08, 2016 07:42 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced… Read More
learn more
December 8, 2016
Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016
Speakers will share new data from Novocure’s phase 2 pilot trials in pancreatic and ovarian cancers Speakers will share new data from Novocure’s phase 2 pilot trials in pancreatic and ovarian cancers December 08, 2016 07:42 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced… Read More
learn more
December 8, 2016
Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016
Speakers will share new data from Novocure’s phase 2 pilot trials in pancreatic and ovarian cancers Speakers will share new data from Novocure’s phase 2 pilot trials in pancreatic and ovarian cancers December 08, 2016 07:42 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced… Read More
learn more
